Kornimate/medical-research-clean huggingface dataset:
effect of physical therapy exercises on cardiorespiratory fitness level in covid19 patients after recovery.

Conditions: Covid19

Summary: in some patients, lung function declined by about 20 to 30% after recovery. computer tomography of covid-19 patients revealed a ground glass opacity in both lungs. we will measure the cardiorespiratory fitness according to american college of sports medicine guidline and provide physiotherapy exercise to the patients to measure the improvement.

in december 2019, the first reports emerged of a novel severe acute respiratory syndrome (sars) coronavirus 2 (sars-cov-2) in wuhan, china. the virus, which causes atypical pneumonia progressing to acute lung injury and acute respiratory distress syndrome (ards) in some individuals, was named covid-19. the burden of fibrotic lung disease following sars-cov-2 infection is likely to be high; therefore, given the scale of the pandemic, the global burden of fibrotic lung disease will probably increase considerably. the aim of this study is to check the cardiorespiratory fitness level and the effect of physical therapy intervention to improve the cardiorespiratory fitness level in patients recovered from covid-19. quality of life has also been affected due to covid19 due to decreased cardiorespiratory fitness level, and this study also aims to improve the quality of life of people recovered from covid19.

Eligibility criteria:
inclusion criteria: * recovered from covid 19 disease (pcr report). * sub-normal performance as compared to normative data. * do not have any respiratory problem. * consent to participate in the study. * able to understand and perform the exercise. * age from 18 to 75. * dyspnea due to covid19. * modified borg dyspnea scale score at least 2 but less than 7. exclusion criteria: * not suffered from covid 19. * respiratory problem. * resting blood pressure greater than 160/100 instead of taking medicine * greater than 1-month post covid19 recovery. * cardiorespiratory comorbidities which limit participation in exercise. * any musculoskeletal problem which limit participation in training. * other cardiovascular morbidity which would limit exercise tolerance (heart failure, abnormal blood pressure responses or st-segment depression \> 2mm, symptomatic aortic stenosis, complex arrhythmias). * unstable angina * orthostatic blood pressure decrease of \>20 mmhg with symptoms * hypertropic cardiomyopathy

Keywords: cardiorespiratory fitness
genetic disorders of obesity program database

Conditions: Obesity, Childhood; Genetic Disease

Summary: this study collects data on children with severe, early-onset obesity.

children and adolescents who have suffered from severe weight gain prior to 5 years of age and who are seen in the genetic disorders of obesity program at texas children are asked to participate in a prospective, observational study. the investigators collect demographic information, body measurements, medical/family history, as well as other questionnaires. additionally, genetic information, medical lab results, and responses to treatment options are collected. the goal of the study is to determine if the investigators can better understand which children would benefit from testing and further workup as well as to understand how obesity develops in these children and adolescents.

Eligibility criteria:
inclusion criteria: * for individuals 2 years and older, bmi \> 97 percentile * for individuals \ 95th percentile exclusion criteria: * no other exclusion criteria
carbetocin versus oxytocin for prevention of postcesarean hemorrhage in pregnancy with high risk for pph

Conditions: Postpartum Hemorrhage; Cesarean Section; High Risk Pregnancy

Summary: objective: study efficacy of carbtocin versus oxytocin for prevention postpartum hemorrhage in high risk pregnancy who undergo cesarean section

randomized controlled clinical trial. defined patient in two group. primary outcome is evaluate additional drug use secondary outcome is evaluated estimated blood loss, hemoglobin level

Eligibility criteria:
inclusion criteria: * previous history of postpartum hemorrhage * polyhydramnios * fetal macrosomia * previous cesarean section * grand multiparity * intramural myoma * chorioamnionitis * prolonged premature rupture of membrane * augmentation of labour exclusion criteria: * pregnancy induce hypertension * on anticoagulant * placenta previa or placenta percreta
observational study of fostamatinib as second line therapy in adult patients with immune thrombocytopenia (itp) and insufficient response to a prior therapy

Conditions: ITP; Immune Thrombocytopenia

Summary: evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of itp in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).

evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of itp in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).

Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent 2. diagnosis of itp in adult patients (≥ 18 years of age) with an insufficient response to steroids ± immunoglobulins and requiring a change in therapy 3. for cohort 1, intent to initiate fostamatinib at enrollment as change in therapy 4. for cohort 2, currently undergoing treatment with fostamatinib as second line therapy for at least 12 weeks, with the intent to continue, at the time of enrollment exclusion criteria: 1. any prior itp therapy/treatment other than steroids ± immunoglobulins (e.g. rituximab, thrombopoietin receptor agonists (tpo), splenectomy) 2. participation in any interventional study during the course of this study 3. lack of historical platelet counts, at time of fostamatinib initiation for those entering cohort 2 4. pregnant and/or nursing

Keywords: immune thrombocytopenia itp
hip fracture surgery in elderly patients

Conditions: Delirium

Summary: the objective of this study is to evaluate the incidence of post-operative delirium (pod), diagnosed with the confusion assessment method (cam), in elderly patients undergoing hip fracture surgery under general anaesthesia with xenon or sevoflurane, for a period of four days post-surgery.


Eligibility criteria:
inclusion criteria: * elderly patient (≥ 75 years) * patient with planned hip fracture surgery within 48 hours after the hip fracture * patient willing and able to complete the requirements of this study including the signature of the written informed consent exclusion criteria: * patient suffering from multiple fractures, pelvic fractures proximal, pathological fractures, femur fractures (i.e., fractures of the middle or distal femur) * disabling neuropsychiatric disorders (severe dementia, alzheimer's disease, schizophrenia, depression) * brain trauma within 12 months prior to selection, history of stroke with residuals * patient suffering from delirium (cam diagnosis) at selection * patient who cannot complete the pre-operative mental tests (cam and/or mmse) of this clinical trial * patient with mini-mental state examination (mmse) score \< 24 at selection * patient known to susceptible to malignant hyperthermia * patient with elevated intra-cranial pressure * patient with a risk of high oxygen demand * patient with recent or ongoing myocardial infarction / damage * patient with severe cardiac failure, or patient with severe impaired left ventricular systolic function * patient with known severe lung and/or airway disease, or severe chronic respiratory insufficiency, or a sustained homecare oxygen therapy * contra-indication (serious illness or medical conditions) for general anaesthesia * known allergy or hypersensitivity to any drugs administered during this clinical trial * previous participation in this clinical trial * participation in another clinical trial within 4 weeks prior to selection * history of alcohol or drug abuse or psychiatric disorders which would impair the understanding of the necessary information or render medically or legally unable to give written informed consent

Keywords: delirium hip fracture elderly
predictors of hfnc failure in patients with ahrf using diaphragm ultrasound

Conditions: Acute Hypoxemic Respiratory Failure

Summary: ultrasound of the diaphragm is an easily reproducible bedside tool that provides a non-invasive measurement of inspiratory muscle function and respiratory efficiency. the diaphragmatic thickness correlates with the strength and muscle shortening and is reflective of its contribution to the respiratory workload. diaphragm thickening fraction (dtf) has been shown to be predictive of extubation failure in ventilated patients. however, whether measurements of dtf are predictive of high flow nasal cannula (hfnc) outcomes in patients with acute hypoxemic respiratory failure (ahrf) remains unknown. the objective of this study is to identify predictors of hfnc failure by diaphragm ultrasound and to compare its performance with the well-established rox index.


Eligibility criteria:
inclusion criteria: * age ≧ 18; and * acute hypoxemic respiratory failure (ahrf), defined by respiratory rate of greater than 25 breaths per minute and a ratio of the pao2 to the fraction of inspired oxygen (pao2 / fio2) of less than 300, and use of accessory muscles of respiration or paradoxical abdominal motion; and * required ventilatory support with high-flow nasal cannula (hfnc) exclusion criteria: * patients suffering from hypercapnic respiratory failure; or * ahrf secondary to conditions that are indicated for non-invasive ventilation (niv) (e.g. acute exacerbation of copd, cardiogenic pulmonary edema); or * use of niv or invasive mechanical ventilation (imv) prior to hfnc initiation; or * patients with imminent need for endotracheal intubation and invasive mechanical ventilation (imv); or * patients with known or suspected diaphragm paralysis; or * pregnancy; or * patients with abdominal compartment syndrome; or * use of hfnc for more than 12 hours prior to icu admission; or * patients with suboptimal diaphragm ultrasound image quality for data processing; or

Keywords: acute hypoxemic respiratory failure high flow nasal cannula diaphragm ultrasound
acetic acid chromoendoscopy to judge gastric intestinal metaplasia

Conditions: Stomach Neoplasms; Metaplasia

Summary: the presence and the extent of gastric intestinal metaplasia(im) is a good indicator of high risk group of gastric cancer. many methods was developed to survey it, including multiple gastric biopsy or methylene blue chromoendoscopy. but they are not practical in the routine screening exam, limited by cost and accessibility. spraying of acetic acid is commonly used in screening cervical cancer, to induce whitish discoloration of metaplastic mucosa. the investigators have confirmed such whitish discoloration is induced in gastric im, with accuracy \> 80% in a pilot study of the investigators. this prospective study will tell the accuracy, sensitivity and specificity of acetic acid chromoendoscopy for judging gastric im.


Eligibility criteria:
inclusion criteria: * person who undergo gastroduodenoscopy * person who visit konyang university hospital exclusion criteria: * bleeding diathesis * history of stomach neoplasms * history of upper gastrointestinal surgery

Keywords: mass screening endoscopy, gastrointestinal stomach neoplasms metaplasia diagnosis acetic acid chromoendoscopy
resveratrol for exudative age-related macular degeneration

Conditions: AMD; Age-related Macular Degeneration; Choroidal Neovascularisation

Summary: this is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of resveratrol to reduce the progression of exudative age-related macular degeneration.

interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of resveratrol to reduce the progression of exudative age-related macular degeneration. comparison of incidence of choroidal neaovascularization between each study group will be performed.

Eligibility criteria:
inclusion criteria: * men or women aged 55 or more with unilateral exudative amd * visual acuity less or equal to 20/25 in the most affected eye exclusion criteria: * allergy to an investigational product * atrophic age-related macular degeneration or age related maculopathy * significant media opacities * other retinal pathology (diabetic retinopathy, high myopia, retinal dystrophy) * recent cataract surgery * previous history of vitrectomy * acute or chronic severe organ failure * present participation in other clinical research study
multiparametric image analysis and correlation with outcomes in lung cancer screening and early stage lung cancer

Conditions: Lung Cancer

Summary: determine whether ct-based multiparametric analytical models may improve prediction of biopsy and treatment outcome in patients undergoing screening ct scan and/or treatment for early stage lung cancer

the hypothesis is that multiparametric models that incorporate complex image information from screening ct scans will improve prediction of the outcome of subsequent lung biopsy, an invasive diagnostic procedure. in this project, we will construct an image feature-based multiparametric prognostic model for biopsy outcome from screening lung ct scans performed at our institution, and then validate it using thenlst imaging and clinical outcomes dataset. this study involves no treatment or invasive procedures. investigator will review all charts of patients who were treated for early stage lung cancer with definitive radiation therapy at utsw or parkland memorial hospital, diagnosed with a malignancy from january 1, 2004 to october 31, 2014, to compile demographic, diagnostic, therapeutic, outcome, and toxicity data. investigator expect that this will include approximately 200 patient charts. this data will be analyzed statistically and used for future directed research. investigator will also analyze an anonymized dataset of patients from the national lung cancer screening trial (nlst) provided by the national cancer institute (nci)

Eligibility criteria:
inclusion criteria: patients that have been diagnosed with lung cancer, and are treated at department of radiation oncology, utsw or parkland memorial hospital. exclusion criteria: there will be no absolute exclusion criteria as long as the inclusion criteria have been met.

Keywords: early stage lung cancer
study of the biovaxid tumor derived idiotype vaccine in patients with follicular lymphoma

Conditions: Non-Hodgkins Lymphoma

Summary: the primary objective of this phase 3 study is to definitively confirm the safety and efficacy of biovaxid, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of disease free survival when administered to patients with indolent follicular non-hodgkin's lymphoma (nhl) during their first complete remission.

patients with stage iii-iv follicular lymphoma and tumor \> 2cm (stage ii allowed if tumor \> 5cm), previously untreated by other than local radiation, provide tumor material by tissue biopsy for production of a patient-specific ig idiotype vaccine conjugated to the immunogenic protein klh. after completing pace or chop-r chemotherapy and achieving a complete remission, followed by a waiting period to reconstitute the immune system, patients who remain in remission randomized to the active treatment arm receive a series of 5 idiotype vaccinations accompanied by the immune stimulant gm-csf. patients randomized to the control arm receive a time-matched series of klh injections also accompanied by gm-csf. patients are subsequently studied to observe their immune responses both to the non-specific immune stimulating agents and for the specific immune response to the vaccine. patients are followed for a minimum of 4 years post-randomization or until relapse.

Eligibility criteria:
inclusion/exclusion criteria: * diagnosis of indolent follicular lymphoma(follicular small-cleaved cell, follicular mixed or follicular large cell with centrocytes) with surface igm or igg phenotype. * stage iii-iv with lymph node \> 2cm or stage ii with lymph node \> 5 cm * no prior chemotherapy other than local radiation (not greater than 2 sites) * ecog \< 2 * survival \> 1 yr * serum creatinine \< 1.5 mg/dl * bilirubin \<1.5 mg/dl * sgot/sgpt \< 3.5 uln * no hiv antibodies or hbv antigen * negative pregnancy screen (females) * no unrelated neoplasm in the previous 10 years * no evidence of primary or secondary cns lymphoma

Keywords: follicular lymphoma non-hodgkins idiotype vaccine indolent follicular non-hodgkins lymphoma tumor-derived b-cell cancer
hearing study: sensitivity to features of speech sounds

Conditions: Hearing Loss, Sensorineural

Summary: the purpose of this study is to better understand the sensitivity of listeners to the fast changes in frequency or amplitude of sounds that occur in speech. the investigators are studying ways to manipulate these aspects of sounds in an effort to make speech sounds more clear.

the investigators will test listeners with normal hearing or with mild or moderate hearing loss. tests will first focus on sensitivity to changes in fast changes in amplitude (loudness) or frequency (pitch) in sounds. then the investigators will test the intelligibility of synthetic vowels and syllables in which these "chirps" are manipulated. finally, the investigators will test intelligibility of words in noise while manipulating sounds in an effort to improve clarity.

Eligibility criteria:
inclusion criteria: * normal hearing, mild or moderate symmetric sensorineural hearing loss. exclusion criteria: * asymmetric hearing thresholds (more than 15 decibels (db) threshold difference between the two ears at any frequency up to 4 khz). * severe hearing loss (greater than 60 db hearing thresholds at any frequency up to 4 khz).
clinical performance of conserved chalky white demineralized enamel cavity margins versus totally removed carious margins in class v cavities restored with composite resin

Conditions: Class V Dental Caries

Summary: this study aims to compare the clinical performance of conserved chalky white demineralized enamel margins with total removal of demineralized enamel margins in class v cavities restored with composite in patients with acute carious cervical lesions

with limited evidence-based information about the clinical performance of conserved white chalky enamel margins in class v .it is beneficial to compare the newly concept of preserved the white chalky deminerlized enamel margins using a randomized clinical trial to test the null hypothesis that this new concept has the same clinical performance as total removal of demineralized enamel margins in class v cavities restored with composite in patients with acute carious cervical lesions .the comparator will be the concept of total removal of demineralized enamel margins in class v cavities restored with composite patients are selected according to the eligibility criteria, local anesthesia will be administered and the operative field will be isolated before starting the restorative procedure. for the comparator group, standard class v cavities will be prepared at labial surface with totally removed carious enamel margins. for interventional group, class v cavity prepared at labial surface with preserved the chalky demineralized enamel margins then applications of remineralizing agent(mi paste plus) before the application of resin composite restoration. local anesthesia will be administered and the operative field will be isolated before starting the restorative procedure. for control group, standard class v cavities will be prepared at labial surface with totally removed carious enamel margins. for experimental group, class v cavity prepared at labial surface with preserved the chalky demineralized enamel margins then applications of remineralizing agent(mi paste plus) before the application of resin composite restoration. both cavities groups restored with resin composite restorations. the restorations are assessed using the modified usphs criteria at the time intervals stated in the outcome measures

Eligibility criteria:
inclusion criteria: * class v carious lesions in premolars and molars. * vital upper or lower teeth with no signs of irreversible pulpitis. * presence of favorable occlusion and teeth are in normal contact with the adjacent teeth. exclusion criteria: * deep carious defects (close to pulp, less than 1 mm distance). * periapical pathology or signs of pulpal pathology. * endodontically treated teeth * tooth hypersensitivity. * possible prosthodontic restoration of teeth. * heavy occlusion or occlusal contacts or history of bruxism. * severe periodontal affection
edoxaban treatment versus vitamin k antagonist (vka) in patients with atrial fibrillation (af) undergoing catheter ablation

Conditions: Atrial Fibrillation

Summary: there are insufficient data on the safety and efficacy of edoxaban therapy in subjects with af following catheter ablation. this phase 3b study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vka-based antithrombotic regimen in subjects with af following catheter ablation. bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.


Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age with documented history of paroxysmal (lasting ≤7 days), persistent (lasting \>7 days but ≤12 months) or long-standing \[long-lasting\] persistent (\>12 months) non-valvular af. duration of af can be confirmed by any electrical tracing or a recording in the subject's medical records (e.g., medical chart, hospital discharge summary). * subject is eligible and is scheduled for either radio frequency (rf) or cryoballoon catheter ablation (both first and repeated procedure included). * signed informed consent form (icf). exclusion criteria: * af considered to be of a transient or reversible nature (such as in myocarditis, post-surgery, ionic disturbances, thyrotoxicosis, pneumonia, severe anemia etc.). * subject post stroke, or with a systemic thromboembolic event within the past 6 months prior to randomization. * subject has a thrombus in the left atrial appendage (laa), left atrium (la), left ventricle (lv), or aorta, or an intracardial mass. * subject had a myocardial infarction (mi) within the 2 months prior to randomization or coronary artery bypass graft (cabg) surgery within 3 months prior to the randomization. * subject has signs of bleeding, history of clinically-relevant bleeding according to international society on thrombosis and hemostasis (isth), or conditions associated with high risk of bleeding * subjects with any contraindication for anticoagulant agents.